New study tests Adebrelimab's Real-World impact on tough lung cancer
NCT ID NCT07434518
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how well the drug adebrelimab works and how safe it is for people with advanced small cell lung cancer in everyday medical practice. Researchers will track 500 patients to see side effects, survival time, and how long the cancer stays under control. The goal is to understand the drug's real-world benefits beyond clinical trials.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER ( SCLC ) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai General Hospital
RECRUITINGShanghai, 201620, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered immune cells take aim at stubborn lung cancer
- Could a hidden nerve condition be more common in lung cancer than we think?
- Can a gentler drug trio tame small cell lung cancer in older patients?
- Experimental combo aims to tackle Treatment-Resistant cancers
- New PET scan targets hidden lung cancer cells
- New drug THE-0504 enters human testing for tough cancers